Skip to main content
. 2021 Jun 29;11:703893. doi: 10.3389/fonc.2021.703893

Figure 2.

Figure 2

Organ and grade distribution of immune-related adverse events in immunotherapy-treated non-small-cell lung cancer patients. (A) Organ distribution of the 232 immune-related adverse events (irAEs) observed in stage IV non-small-cell lung cancer (NSCLC) patients (p < 0.0001 with a chi-square test across the various affected organs; detailed results are shown in Table 2 ; ***p < 0.001, **p < 0.01, *p < 0.05). (B) Grade distribution of the 232 irAEs observed in stage IV NSCLC patients (p < 0.0001 with a chi-square test across grades, grades with significantly increased frequency are marked with asterisks). (C) Grade distribution of the irAEs observed in each organ for stage IV NSCLC patients. For each organ, the p-value was calculated with a chi-square test of the observed frequencies for each grade against the even distribution (endocrinological: 44 irAEs overall, grade 1:7, grade 2:25, grade 3:9, grade 4:3, p < 0.001; lungs: 40 irAEs overall, grade 1:2, grade 2:9, grade 3:20, grade 4:8, grade 5:1, p < 0.001; musculoskeletal system: 38 irAEs overall, grade 1:3, grade 2:27, grade 3:8, grade 4:0, p < 0.001; colon: 37 irAE overall, grade 1:3, grade 2:11, grade 3:16, grade 4:7, p = 0.02; hepatitis: 33 irAEs overall, grade 1:2, grade 2:7, grade 3:20, grade 4:4, p < 0.001; skin: 23 irAEs overall, grade 1:8, grade 2:11, grade 3:4, grade 4:0, p = 0.0075; nervous system: six irAEs overall, grade 1:0, grade 2:3, grade 3:3, grade 4:0, p = 0.06; heart: four irAEs overall, grade 1:0, grade 2:1, grade 3:1, grade 4:1, grade 5:1, p = 0.26; kidneys: three irAEs overall, grade 1:0, grade 2:1, grade 3:0, grade 4:2, p = 0.30; pancreas: three irAEs overall, grade 1:0, grade 2:1, grade 3:1, grade 4:0, p = 0.80; hematological: one irAE overall, grade 3).